UK markets closed

AERI Nov 2021 20.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.05000.0000 (0.00%)
As of 2:16PM EDT. Market open.
Full screen
Previous close1.0500
Open0.9500
Bid0.5000
Ask1.4000
Strike20.00
Expiry date2021-11-19
Day's range0.9500 - 1.0500
Contract rangeN/A
Volume2
Open interest15
  • Aerie Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call on Wednesday, August 4, 2021
    Business Wire

    Aerie Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call on Wednesday, August 4, 2021

    DURHAM, N.C., July 28, 2021--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced today that its first quarter 2021 financial results will be released after the market closes on Wednesday, August 4, 2021. Following the release, the Company will host a live conference call

  • Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit European Innovation Showcase
    Business Wire

    Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit European Innovation Showcase

    DURHAM, N.C., July 20, 2021--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that David A. Hollander, M.D., M.B.A., Chief Research & Development Officer presented an overview on Aerie’s globalization outlook at the Ophthalmology Innovation Summit European Innov

  • Aerie Pharmaceuticals Announces Appointment of Leon J. Atencia, Director of Regulatory Affairs
    Business Wire

    Aerie Pharmaceuticals Announces Appointment of Leon J. Atencia, Director of Regulatory Affairs

    DURHAM, N.C., July 15, 2021--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced the appointment of Leon J. Atencia, Director of Regulatory Affairs, reporting to Emma Beausang, Aerie’s Vice President of Regulatory Affairs. Mr. Atencia will be responsible for clinical